Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer

Category Primary study
JournalEuropean Journal of Cancer
Year 2016
This article has no abstract
Epistemonikos ID: f83598493a8e4f12fd579c01db5a97aa71a80799
First added on: Feb 08, 2025